Page Menu

Moffitt Researchers Identify Novel Target to Improve Chemotherapeutic Response in Breast Cancer

Dendritic Cell

In an article published in the January issue of Cancer Cell, members of the Department of Immunology at Moffitt report that TIM-3 is expressed by intratumoral CD103+ dendritic cells – the cells responsible for the initial activation of anti-tumor T cells – and alters their immunostimulatory function. 

Accordingly, anti-TIM-3 antibody administration leads to superior anti-tumor activity by CD8+ T cells and an immune-mediated response to chemotherapy. These findings expand upon the potential targets of TIM-3 antibodies currently in clinical trials, and offer a rationale for combinatorial studies with chemotherapy in breast cancer and other solid malignancies. The team was led by Dr. Brian Ruffell, assistant member at Moffitt Cancer Center. Reference: de Mingo Pulido et al., 2018, Cancer Cell 33, 60–74.